- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00130819
Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
Buprenorphine Effectiveness Evaluation in HIV Enhancement (BEEHIVE): A Randomized Trial of HIV Clinic-based Buprenorphine/Naloxone vs. Case Management and Referral in Opioid-dependent Individuals
The purpose of this study is to compare the effectiveness of two approaches to treating HIV-infected patients who are addicted to opioid drugs (e.g., heroin) in an inner-city HIV clinic. The two approaches are:
- Case management and referral - participants are managed by a case manager and referred to a specialized drug treatment center where they receive counseling and medications for opioid-dependence (e.g., methadone or buprenorphine); or
- Clinic-based treatment - participants receive counseling and treatment with buprenorphine at the HIV clinic.
Descripción general del estudio
Estado
Descripción detallada
We, the investigators at Johns Hopkins University, propose to enroll and randomize 120 opioid-dependent, HIV-infected participants, who receive care in the Johns Hopkins HIV Clinic to either:
- clinic-based care with buprenorphine (clinic-based BPN/NX arm); or
- case management and referral to an opioid treatment program for opioid agonist-based therapy (case management and referral arm).
The study interventions and follow-up will last 12 months. Participants will be enrolled over a 3-year period. Participants who are assigned to the clinic-based BPN/NX arm will receive BPN/NX (Suboxone®), individual counseling from a nurse interventionist, and group therapy sessions. Participants who are assigned to the case management and referral arm will be enrolled in an established case management and adherence program in the Johns Hopkins HIV Clinic (Project LINK). LINK provides intensive case management, education, and support by a team that includes a social worker, a nurse, a pharmacist educator, and peer advocates. In addition to providing counseling and linkage to needed services, LINK will expedite intake at licensed opioid treatment programs that provide agonist-based therapy for opioid dependence. The clinic-based BPN intervention is a new strategy that was developed in a pilot project over the past 6 months. The case-management and referral arm represents standard-of-care in our clinic, which has been enhanced and codified for this trial. Study outcome visits will be performed at baseline, 1 month, 3 months, 6 months, 9 months, and 12 months.
Comparisons:
- Retention to substance abuse treatment;
- Urine drug screens;
- Adherence to HIV primary care provider visits;
- Use of and adherence to highly active antiretroviral therapy (HAART);
- HIV RNA levels and CD4 cell counts;
- HIV transmission risk behaviors (e.g., injection, sharing of drug paraphernalia, sexual behaviors);
- Costs and resource utilization.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Johns Hopkins HIV Clinic
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- HIV-infected and receiving continuity care in the Johns Hopkins HIV Clinic
- 18 years of age or older
- Meets DSM-IV criteria for opioid dependence
- Seeks agonist-based treatment for opioid dependence
- Willing and able to provide written informed consent
- Willing to be contacted by mail and telephone for study follow-up visit reminders
- Willing to authorize release of information for substance abuse treatment to the study for a period of 12 months
- If female, negative urine pregnancy test and willingness to practice birth control while on study if sexually active (barrier method or progesterone-containing contraception product)
- Verbal approval from participant's primary HIV clinician
Exclusion Criteria:
- Currently receiving methadone, naloxone, buprenorphine, or levomethadyl acetate (LAAM) as part of a licensed opioid treatment program
- History of allergic reaction to buprenorphine or naloxone
- Active medical need for opioid-based pain control
- Active benzodiazepine abuse or dependence
- Active alcohol dependence
- Alanine aminotransferase level that is more than 5 times the upper limit of normal
- Other condition that, in the opinion of the principal investigator, makes participation in the study unsafe or follow-up highly unlikely
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: 1
Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
|
Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
|
|
Comparador activo: 2
Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
|
Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Retención al tratamiento por abuso de sustancias
Periodo de tiempo: 12 meses
|
12 meses
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Comportamientos de riesgo de transmisión del VIH autoinformados
Periodo de tiempo: 12 meses
|
12 meses
|
|
Visit attendance with primary medical provider
Periodo de tiempo: 12 months
|
12 months
|
|
Urine drug screen positivity for opioids and other drugs
Periodo de tiempo: 12 months
|
12 months
|
|
Use of and adherence to highly active antiretroviral therapy (HAART)
Periodo de tiempo: 12 months
|
12 months
|
|
HIV RNA changes
Periodo de tiempo: 12 months
|
12 months
|
|
CD4 cell count changes
Periodo de tiempo: 12 months
|
12 months
|
|
Costs and resource utilization
Periodo de tiempo: 12 months
|
12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Gregory M Lucas, MD, PhD, Johns Hopkins University
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Desordenes mentales
- Trastornos inducidos químicamente
- Trastornos relacionados con sustancias
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Trastornos relacionados con narcóticos
- Infecciones por VIH
- Seropositividad al VIH
- Trastornos relacionados con opioides
- Efectos fisiológicos de las drogas
- Depresores del sistema nervioso central
- Agentes del sistema nervioso periférico
- Analgésicos
- Agentes del sistema sensorial
- Analgésicos Opiáceos
- Estupefacientes
- Antagonistas de narcóticos
- Buprenorfina
Otros números de identificación del estudio
- H97HA03794
- HRSA-04-078
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .